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ABSTRACT
Objectives Faecal serine proteases (FSPs) may play a
role in irritable bowel syndrome with diarrhoea (IBS-D),
but their origin is unclear. We aimed to structurally
characterise them and deﬁne the impact of colonic
cleansing and transit time.
Design Faecal samples were obtained from 30 healthy
volunteers (HV) and 79 patients with IBS-D participating
in a trial of ondansetron versus placebo. Colonic transit
was measured using radio-opaque markers. Samples
were also obtained from 24 HV before and after colonic
cleansing with the osmotic laxative MoviPrep. FSPs were
puriﬁed from faecal extracts using benzamidine-
Sepharose afﬁnity chromatography. SDS-PAGE proﬁled
components were identiﬁed using trypsinolysis and
tandem mass spectrometry. Functional protease activity
in faecal extracts was measured using a colorimetric
assay based on the proteolysis of azo-casein.
Results Protein analysis identiﬁed the most abundant
FSPs as being of human origin and probably derived
from pancreatic juice. Functional assays showed
increased faecal protease (FP) and amylase in patients
with IBS-D compared with HV. Those with higher
amylase had signiﬁcantly higher FP and greater anxiety.
FP activity correlated negatively with whole gut transit in
patients with IBS-D (Spearman r=−0.32, p=0.005) and
HV (r=−0.55, p=0.014). Colon cleansing caused a
signiﬁcant rise in FP activity in HV from a baseline of
median (IQR) 253 (140–426) to 1031 (435–2296),
levels similar to those seen in patients with IBS-D. FSP
activity correlated positively with days/week with
urgency.
Conclusions The most abundant FSPs are of human
origin. Rapid transit through the colon and/or decreased
(possibly bacterial) proteolytic degradation increases
their faecal concentration and could contribute to
visceral hypersensitivity in patients with IBS-D.
ClinicalTrials.gov NCT00745004.
BACKGROUND
Irritable bowel syndrome (IBS) is a ubiquitous con-
dition characterised by abdominal pain or discom-
fort and altered bowel habit, reported by up to
10% of the population.1 The cause is essentially
unknown, but several subtypes are recognised
based on differing stool patterns including IBS with
diarrhoea (IBS-D), IBS with constipation (IBS-C)
and a mixed bowel habit (IBS-M) where stool
consistency varies erratically. The precise cause of
the disturbed bowel habit is unknown, but there
has been much interest in recent reports that the
faeces of patients with IBS-D have increased faecal
serine protease (FSP) activity.2 These proteases have
been shown to be the active component of faecal
supernatants from patients with IBS-D which,
when instilled into the mouse colon, act via PAR-2
receptors to cause increased permeability, mucosal
inﬂammation and visceral hypersensitivity—charac-
teristic features of IBS.3 These FSPs have so far
only been assessed using functional assays and have
not been structurally identiﬁed, so their origin is
unclear. It has been shown that they are also
increased in patients with ulcerative colitis but not
in IBS-C or IBS-M, healthy controls, nor indivi-
duals with acute infectious diarrhoea—facts which
has been used to argue that accelerated transit was
not the cause of increased serine protease activity.
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Signiﬁcance of this study
What is already known about this subject?
▸ Patients with irritable bowel syndrome and
diarrhoea (IBS-D) have increased faecal serine
protease activity which may contribute to
colonic hypersensitivity.
▸ The origin of the faecal proteases is unclear.
What are the new ﬁndings?
▸ Protein characterisation suggests the most
abundant faecal serine proteases are human
and probably pancreatic in origin.
▸ Bowel cleansing increases faecal protease
activity, suggesting that bacteria degrade
endogenous pancreatic proteases.
▸ Faecal protease activity is positively correlated
with days/week with urgency and negatively
correlated with colonic transit.
How might this impact on clinical practice in
the foreseeable future?
▸ Increased faecal protease activity could
exacerbate IBS-D symptoms by sensitising the
rectum to distension and could be a new
therapeutic target for the treatment of IBS-D.
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Previous work showed that serine proteases were unlikely to be
of mast cell origin since mast cell tryptase was not increased,4
nor were they thought to be of neutrophil origin since neutro-
phil markers such as myeloperoxidase4 or calprotectin5 are not
elevated in IBS-D. We hypothesised that these FSPs are likely to
be of bacterial origin. Inhibiting these with protease inhibitors
can reverse the colonic hypersensitivity induced in animal
models, suggesting that reducing faecal proteases (FPs) might be
a therapeutic target in patients with IBS.2
The aim of this study was therefore to characterise FSPs both
structurally and functionally in patients with IBS and healthy
controls to determine their origin as a ﬁrst step to devising a
therapeutic intervention to reduce visceral hypersensitivity in
IBS. Our initial protein sequencing studies6 suggested that the
enzyme activity was likely to be of human origin. We hypothe-
sised that increased FP activity might be due to accelerated
transit and/or altered faecal microbiota reducing bacterial deg-
radation which normally accounts for the 20-fold fall in prote-
ase activity in human faeces compared with ileostomy output.7
We tested this hypothesis indirectly by examining the correlation
of total FP activity with speciﬁc immunoassays for pancreatic
elastase and pancreatic α-amylase and also with whole gut
transit. Finally, we accelerated transit and reduced faecal micro-
biota by using an osmotic laxative polyethylene glycol and
showed that this increased FP activity.
METHODS
The study consisted of two parts. Part 1 was descriptive and
method development and involved the ﬁrst 36 patients with
IBS-D entering a randomised placebo controlled trial of ondan-
setron and nine healthy controls. Since our studies showed a
possible effect of colonic transit on faecal levels of another pan-
creatic enzyme (amylase), Part 2a involved assessment of the
correlation with transit in 79 patients with IBS-D while Part 2b
examined the effect of colonic cleansing using an osmotic laxa-
tive MoviPrep in 24 healthy volunteers.
Participants
Healthy controls were recruited by advertisement and com-
pleted a Rome III questionnaire to exclude a diagnosis of IBS.
All denied abdominal pain or discomfort.
Patients with IBS had already completed a full negative evalu-
ation for other diseases in the Nottingham University Hospital
NHS Trust gastroenterology outpatient clinic prior to entry into
a randomised placebo-controlled crossover trial of ondansetron
in 2009–2011, the results of which have been presented in
abstract form8 and will be published separately.
Patients were aged 18–75 years and met Rome III criteria for
IBS-D with at least 25% of the stools having a stool form score
of 6 or 7 on the Bristol Stool Form Score (BSFS) and no more
than 25% with a stool form score of 1 or 2. Patients completed
a stool diary during a 2-week run-in period to conﬁrm they met
criteria before enrolment. They also completed the Hospital
Anxiety and Depression Score and the Rome III questionnaire.
Patients were excluded if they had had abdominal surgery other
than appendicectomy and cholecystectomy or were unable to
stop antidiarrhoeal drugs. The evaluation included a detailed
history, examination, sigmoidoscopy and biopsy, full blood
count, haematinics, electrolytes, tissue transglutaminase anti-
body, thyroid function, calcium, liver function tests as well as
colonoscopy and biopsy to exclude microscopic colitis. Bile salt
retention testing (selenium-75 homocholic acid taurine,
SeHCAT) was performed where there was high-volume diar-
rhoea or nocturnal symptoms. Patients were instructed to drink
one pint of skimmed milk after an overnight fast to screen for
lactose intolerance. Those who developed symptoms were then
tested with a formal breath hydrogen 50 g lactose tolerance test
and those whose symptoms responded to a lactose-free diet
were excluded.
Study design
The study comprised two parts. During Part 1 we structurally
characterised the components detected in the selectively
enriched serine protease fraction and assessed total FP activity
as well as performing independent immunoassay of other pan-
creatic enzymes (ie, elastase and amylase) in a subgroup of the
patients with IBS (n=36) using their baseline samples before
they received any treatment. These studies suggested that transit
inﬂuenced faecal levels of at least one pancreatic enzyme
(amylase), so in Part 2 we correlated FP with transit which were
both measured after 5 weeks of placebo in the whole IBS-D
patient cohort (n=79) (Study 2a). Furthermore, since previous
studies have suggested that bacterial degradation reduced FP, we
examined the effect of bowel cleansing in 24 healthy controls
(Study 2b).
Part 1
Healthy controls (n=9) were asked to complete a 1-week stool
diary documenting stool form using the BSFS, stool frequency
and bowel symptoms including bloating, abdominal pain and
urgency on a daily basis. They also provided a stool sample.
Thirty-six patients with IBS-D entering our ondansetron RCT
provided identical information as part of their baseline data
before commencing the trial. The demographic characteristics
of both groups are shown in table 1.
Part 2a: Effect of ondansetron
The RCT of ondansetron was a 5-week crossover study with a
2–3-week washout period to ensure return to previous bowel
habit. We used dose titration to optimise the response and avoid
excessive constipation. Doses used ranged from 4 mg every
other day to 8 mg three times daily. The ﬁnal dose was main-
tained unchanged for the ﬁnal 2 weeks when colonic transit was
measured. On day 4 of the transit measurement the stool
sample was provided to be analysed for FP for correlation with
transit. Here we report only the values of FP obtained in the
ﬁrst 36 patients at baseline and all 79 patients who provided a
suitable sample and had colonic transit measured during the
placebo arm of the study. A total of 128 patients completed the
multicentre trial but lack of stool sample (17) at the appropriate
time and/or lack of valid transit measurement (29) meant that
Table 1 Subject demographics
Patient
group N
Gender
M/F
Age years
Mean
(SEM)
Bowel
movements/day
Median (IQR)
Anxiety
HADS
Mean (SEM)
Part
1
Healthy
volunteers
9 3/6 25.4 (2.3) 1.4 (0.7–2.0) ND
IBS-D 36 11/25 39 (2) 2.8 (2.1–4.2) 9.0 (0.8)
Part
2a
Healthy
volunteers
21 5/16 42.8 (4) 1.1 (1–1.4) 5.2 (0.6)
IBS-D 79 22/57 41 (2) 2.7 (2–3.9) 9.2 (0.6)
Part
2b
Healthy
volunteers
24 12/12 26.5 (3) 1.3 (1.1–1.5) 3.5 (0.7)
HADS, Hospital Anxiety and Depression Score; IBS-D, irritable bowel syndrome with
diarrhoea; ND, not done.
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here we analyse a subset of 79 with complete data. There was,
however, no signiﬁcant difference in demographics and
symptom severity from those who did not provide complete
data (see online supplementary table S1 appendix), so the sub-
jects whose data are presented here are representative of the
study group as a whole. We also recruited an additional 21
healthy controls, attempting to age and sex match our patient
group. They completed a 1-week stool diary documenting
bowel frequency, stool form of each stool using the BSFS, and
whether there was abdominal pain or urgency for each day.
They also completed the same questionnaires as those used in
the RCT and underwent the same whole gut transit measure-
ment. Demographic details are shown in table 1.
Part 2b: Effect of osmotic laxative MoviPrep
This was part of an imaging study demonstrating the increase in
small bowel and colonic water after MoviPrep ingestion.9 As
part of that study we collected stool samples to assess bacterial
numbers and FP levels. Stool samples were collected using our
standard protocol outlined below on the day before and 2, 14
and 28 days after purging with either a single dose of 2 L
MoviPrep or two 1 L doses taken 12 h apart. Subjects ate a low
residue diet the night before each study. This induced pro-
nounced loose watery stools in both groups and, as expected,
signiﬁcantly reduced bacterial abundance.
Stool collection
Stool samples were collected at home by all subjects using three
separate pots (Sterilin UK) on the morning of the visit and were
delivered to the research centre within 2 h of defaecation when
they were immediately frozen at −70C°. Quantitative PCR using
a universal bacterial probe was used to assess total bacterial
count/abundance.
Measurement of whole gut transit
Transit was measured using the Metcalf method.10 Patients
ingested 20 radio-opaque markers on the morning of days 1–3
and had a plain abdominal x-ray on day 4 to count the number
of pellets remaining. Transit was calculated in hours from the
formula 1.2×number of remaining pellets as validated by
Metcalf.10
Structural characterisation of FSPs
We characterised the FSPs using the workﬂow outlined in
ﬁgure 1.
Extraction and stabilisation of proteins from faecal samples
Samples (1 g) of stool stored at −70°C were thawed and mixed
in 5 mL 50 mM Tris buffer, 150 mM NaCl, pH7.2. Turbid sus-
pensions were clariﬁed using a sequential combination of centri-
fugation (10 min, 3000 RCF) and ﬁltration (0.2 μm). Particulate
free supernatants were archived (−70°C) until required for
various assays or protein characterisation procedures.
Quantitation of total protein
Total protein quantitation was performed using the Bradford
method11 modiﬁed for low volume and high throughput.
Brieﬂy, equal volumes of sample and reagent were mixed in
96-well microplates and, following 20 min incubation, absorb-
ance measurements at 595 nm were used to quantitate by refer-
ence to bovine serum albumin calibrants.
Quantitation of total protease activity
Total FP quantitation was performed using the non-speciﬁc
proteolysis of azo-casein. The endoproteolysis of this liberates
azo-peptides into the supernatant which are quantitated by
absorbance measurement at 440 nm subsequent to protein pre-
cipitation with trichloroacetic acid. Protease activity was quanti-
tated against bovine trypsin calibrant and expressed as trypsin
units. Protein concentrations ranged from 0.08 to 1.7 mg/mL
Figure 1 Methods and workﬂow.
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and measured protease activities were normalised against these
values and expressed as units of trypsin/mg protein.
The protocol was essentially as described by Roka4 but was
optimised to a high-throughput assay by application of 96-well
microplates for extraction, incubation, clariﬁcation and absorb-
ance plate reading and employing serial dilutions of test samples
and calibrant. This enabled multiple positive and negative con-
trols, calibration standards and samples at multiple dilutions and
replicates to be rapidly processed. The serine protease inhibitor
aprotinin was added to trypsin standards and faecal extracts at a
range of concentrations and showed a concentration-dependent
inhibition. At the higher dose of 100 μg/mL aprotinin, all FP
from patients with IBS-D was inhibited (n=7), suggesting most
FP is in fact FSP.
Afﬁnity chromatographic puriﬁcation of serine proteases
We puriﬁed FSP by passing 0.45–0.55 mg total protein in faecal
extracts through 0.25 mL benzamidine-Sepharose resin (GE
Healthcare, Amersham, UK) which speciﬁcally retains serine
proteases in centrifugal spin columns. Samples were loaded and
washed in 0.5 mL 50 mM Tris, pH 7.4, 0.5 M sodium chloride
buffer and retained components were eluted using 0.5 mL
50 mM glycine pH 3.0 buffer. Proteins in eluate fractions were
desalted using reversed phase solid-phase extraction essentially
according to published procedures12 and characterised subse-
quently by SDS-PAGE proﬁling.
Protein electrophoresis
SDS-polyacrylamide gels (4–12% Bis-Tris using MES buffer,
Invitrogen, Paisley, UK) were electrophoresed under thiol-
reducing conditions according to vendor guidelines. Protein
components were visualised by chemical staining using colloidal
Coomassie Brilliant Blue G-250 (Pierce, Gelcode Blue) accord-
ing to vendor guidelines.
Identiﬁcation of protein components
Protein components in gel lanes were excised, reduced using
dithiothreitol, alkylated using iodoacetamide and proteolysed
using (Promega sequencing grade) porcine trypsin in 0.1 M
ammonium bicarbonate, pH 8.0. All protocols were standard
procedures essentially according to Hellman et al.13
Proteolytic peptides were extracted, captured and desalted
to a chromatographic trap (Dionex C18, 0.3×5 mm) and sub-
jected to microcapillary high-pressure liquid chromatography
(Phenomenex Jupiter Proteo 4 μm, 0.075×150 mm) with
tandem mass spectrometry (nano-LC-MS/MS) using a hybrid
quadrupole time-of-ﬂight (Waters Q-TOF2) instrument
equipped with a nano-electrospray ion source in positive ion
mode and calibrated against synthetic peptide product ions.
Data-dependent product ion spectra were acquired ‘on-the-ﬂy’
during test experiments. The MASCOT server (http://www.
matrixscience.com) was used to interrogate the SWISS-PROT
databases using total pooled precursor and product ion data and
reports were compiled together with total molecular weight
search (MOWSE) probability scores.
Assessment of faecal amylase and elastase using immunoassays
Since our proteomic analysis suggested that a major serine pro-
tease component was trypsin, we decided also to assay pancre-
atic amylase and elastase. While trypsin and amylase are
degraded by faecal bacteria and so normally excreted in only
small amounts, elastase is more stable and readily detectable in
stool and used widely to detect pancreatic insufﬁciency.
Proprietary ELISA kit products were used to quantitate these
other pancreatic enzymes in stool extracts—namely, Pancreatic
Amylase ELISA (Biosupply, Bradford, UK) and elastase (ScheBo
Pancreatic Elastase-1 Stool Test, Giessen, Germany).
In brief, the Pancreatic Amylase sandwich ELISA is performed
by incubating the sample with immobilised mouse monoclonal
antibodies to human pancreatic amylase. After washing these are
incubated with a second anti-pancreatic amylase antibody linked
to peroxidase and the amount bound assessed from the colour
developed with the substrate tetramethylbenzidine. The ScheBo
Pancreatic Elastase-1 Stool Test similarly uses an immobilised
monoclonal antibody to human pancreatic elastase to bind the
elastase. After incubation with a second biotinylated antibody,
the bound antigen-antibody complex is detected by incubation
with peroxidase/streptavidin and peroxidase activity is detected
using the chromogen 2,20-azoni-bis-3-ethylbenzothiazolin-6-
sulphonic acid and assessing the spectroscopic absorbance at
405 nm. The intra-assay coefﬁcient variation of repeated mea-
sures (CV) for elastase and amylase was 5.3% and 8.9%,
respectively, and inter-assay CV was 14% and 11%, respectively.
A ﬂuorescence reporter assay system (PHADIA-CAP, Phadia,
Uppsala, Sweden) was also used to speciﬁcally quantitate mast
cell tryptase. The assay was found to give undetectable readings
when samples were spiked with human pancreatic trypsin (data
not shown). The limit of detection was 1 μg/L.
Statistical analysis
Values were assessed for normality using the Shapiro–Wilks stat-
istic and the results are expressed as mean (SEM) for normally
distributed data or median (IQR) if not normally distributed.
Differences in FP activity between controls and patients with
IBS-D were assessed using the Mann–Whitney U test while
faecal elastase differences were assessed using the Student t test.
Differences between visits for the MoviPrep study were assessed
using repeated measures ANOVA while the correlation between
transit and FP activity was assessed using the non-parametric
Spearman correlation test.
Correlations between FP activity and symptoms were assessed
initially using the Spearman non-parametric test and then logis-
tic regression was performed to predict values of FP above or
below the mean value of 467 trypsin units/mg protein. The four
variables shown to have signiﬁcant correlations with FP levels
were entered into a backwards conditional logistic regression
model.
Power calculations
The initial studies were exploratory and so no power calculation
could be performed. The ondansetron and MoviPrep trials were
powered to show a change in stool consistency and changes in
small bowel water content, respectively, while the faecal
enzymes were secondary endpoints. However, the effect size of
the MoviPrep purge was very substantial and we had a 90%
power to detect a change of −101 trypsin units/mg, very much
smaller than actually observed (778 trypsin units/mg).
RESULTS
Selective puriﬁcation of serine proteases from faecal
supernatant
Using a test mixture of bovine trypsinogen and equine myoglo-
bin, we were able to demonstrate high selectivity of the
benzamidine-Sepharose resin (see online supplementary appen-
dix ﬁgure S1). When chromatographed, buffered faecal extracts
from patients with IBS and controls similarly yielded retained
components that, when proﬁled using micropreparative
SDS-PAGE, yielded heterogeneous mixtures of components
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with a broad molecular size range (ﬁgure 2). As can be seen,
several components were selectively retained and their relative
abundance was increased in patients compared with healthy
controls. Four representative molecular weight gel regions were
excised and the human proteins α-amylase 2A and 2B,
trypsin-1, -2 and -3, chyomotrypsin-like elastase 3B, carboxy-
peptidase B and α1-antitrypsin were identiﬁed (table 2) using
proteomic procedures. A summary of the proteomics results is
shown in online supplementary appendix table S2 and conﬁrms
the high speciﬁcity of the generated results, together with the
high statistical signiﬁcance and conﬁdence in assigned identiﬁca-
tions. There is inherently high homology between the various
trypsin proteins, but multiple sequence alignment analyses (see
online supplementary appendix ﬁgure S3) clearly show that
there were data speciﬁc to each of the three gene products and
also that autolytic fragments of the employed porcine trypsin
sequencing proteinase did not contribute any spurious result.
Tryptases have been implicated in IBS, and there are documen-
ted sequence homologies between trypsins and tryptases.
However, multiple sequence alignments (see online
supplementary appendix ﬁgure S4) clearly show that all detected
peptide sequence results were uniquely speciﬁc to trypsins—that
is, no primary sequence identiﬁed was common to tryptases.
FP activity in patients with IBS-D versus healthy controls
FP activity was measured in the ﬁrst 36 patients with IBS-D and in
9 healthy controls. FP showed wide variability and was non-
normally distributed in patients with IBS-D (Shapiro–Wilks
W=0.8, p=0.0003) but not in healthy controls. Values were sig-
niﬁcantly increased in patients with IBS-D compared with healthy
controls (median (IQR) 451 (61–963) vs 147 (IQR 82–336) units
trypsin/mg protein, p=0.038, Mann–Whitney U test).
Faecal levels of elastase and amylase in patients
with IBS-D versus controls
Faecal elastase values were normally distributed but were not
signiﬁcantly different in patients with IBS-D and healthy con-
trols (mean±SEM 2.4±0.2 vs 2.5±0.4 μg/mg stool, p=0.85,
n=36). Pancreatic amylase (ﬁgure 3) showed a biphasic distribu-
tion which was somewhat higher in patients with IBS than in
healthy controls (median (IQR) 122.4 (0.48–325.2) vs 17.0
(10.3–102.8) units/mL), but this did not achieve statistical sig-
niﬁcance (p=0.07).
However, there was a clear gap between the value of 27.3 μ/L
and the next value of 105.1 μ/L, suggesting two groups within
the patients with IBS. If those with faecal amylase values
>27.3 μ/L were compared with those with lower values, they
had signiﬁcantly higher FP (634 (220–1322) vs 276 (111–485)
trypsin units/mg protein, p=0.03 Mann–Whitney U test) and
greater anxiety scores (11.1 (1.1) vs 6.4 (0.8), p=0.006).
Although transit was numerically shorter (21.8 (4.2) h vs 27.4
(4.1) h), this difference was not signiﬁcant.
Mast cell tryptase
Using the Phadia Immunocap assay for mast cell tryptase, we
found undetectable levels (<0.1 μg/L) in stool samples from 79
Figure 2 SDS-PAGE of benzamidine-Sepharose enriched fraction of faecal extract samples. SDS-PAGE of chromatographic fractions of faecal
extracts from patients with irritable bowel syndrome with diarrhoea (IBS-D) and healthy volunteers. Individual reference numbers are shown and red
boxes denote representative regions excised for component identiﬁcation. Note that similar proﬁles of components were recovered for all diseased
individuals and that little or no protein was detected in healthy volunteers except for one individual who showed an SDS-PAGE proﬁle comparable
with IBS-D patients. Retrospectively it was apparent she did experience pain and some urgency though not enough to meet Rome criteria. The
average transit time of these nine IBS patients was 21 h, stool frequency 3.0/day and urgency score 1.3 on a 0–3 scale, which is typical for the
group whose average values were 19 h for transit, stool frequency 2.6/day and urgency score 1.6.
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patients with IBS-D and 20/21 healthy controls, even though
spiking the sample with pure human mast cell tryptase (MCT,
Sigma-Aldrich, Warrington, UK) did show that it could be
detected in stool at concentrations down to 5.5 μg/L.
Effect of colonic cleansing in healthy controls using
MoviPrep
Twenty-three subjects completed the trial. Both the double dose
of 1 L and the single dose of 2 L MoviPrep induced pronounced
loose watery stools and an average 31-fold fall in bacterial
counts on day 2 (data not shown). FP activity in stool samples
passed on day 2 (day after the purge) was signiﬁcantly elevated,
rising from a median (IQR) of 253 (140–426) trypsin units/mg
at visit 1 to 1031 (435–2296) at visit 2, falling again to baseline
at day 14 (258 (149–547)) and 236 (156–310) trypsin units/mg
on day 28 (ﬁgure 4). One-way ANOVA showed a signiﬁcant
effect of time (p=0.001), post hoc comparison showed signiﬁ-
cantly higher levels at visit 2 than at visit 1 (p=0.0007
Wilcoxon test, n=23).
Correlation with transit in IBS-D
Seventy-nine samples from the placebo arm of the ondansetron
trial were matched with colonic transit measurements and 21
healthy, age- and sex- matched volunteers. As with the baseline
values of the ﬁrst 36 patients, there was wide variability in FP
levels in the larger group from the placebo arm and, although
the values for patients with IBS were numerically greater than
those for the matched healthy controls (median (IQR) 501
(245–1421) trypsin units/mg protein vs 302 (147–4) trypsin
units/mg protein), the difference was not signiﬁcant. If we
combine all the healthy controls from parts 1 and 2, the control
FP value is 302 (147–475) trypsin units/mg protein (n=51) and
the difference from IBS-D is signiﬁcant (p=0.003) but, as ﬁgure 5
shows, there is a wide variation in both groups. In order to
understand this variation we correlated transit and FP activities
measured in patients with IBS-D on placebo which showed a
signiﬁcant negative correlation (Spearman r=−0.32 (95% CI
−0.51 to 0.09), p=0.005, n=79, ﬁgure 6). A similar result was
also found in healthy controls for whom we had transit mea-
surements (Spearman r=−0.55 (95% CI −0.81 to 0.11),
p=0.014, n=20). FP activity also correlated signiﬁcantly with
the average urgency in patients with IBS patients (Spearman
r=0.26 (95% CI 0.03 to 0.47), p=0.02, n=73, ﬁgure 7).
There were no correlations with the average daily pain score
and stool frequency (p=0.18 and 0.75, respectively). However,
there was a signiﬁcant correlation with anxiety (r=0.30,
p=0.01), depression (r=0.3, p=0.01) and psychological distress
(r=0.3, p=0.01). These psychological variables are closely
Figure 4 Faecal protease (FP) activity expressed in trypsin units/mg
protein after colonic cleansing with MoviPrep at day −1 and days 2, 14
and 28 showing a signiﬁcant rise in FSP activity after purging of
colonic bacteria. One-way ANOVA for effect of time (p=0.001; day −1
vs day 2, p=0.0007, n=23).
Figure 5 Faecal protease activity expressed in trypsin units/mg
protein showing that patients with irritable bowel syndrome with
diarrhoea had signiﬁcantly higher values than controls, but with wide
variability in both groups. **p=0.003 (Mann–Whitney U test).
Figure 3 Faecal levels of amylase in patients with irritable bowel
syndrome with diarrhoea (IBS-D) versus controls showing a biphasic
distribution with one group of 22 showing a signiﬁcant increase while
a subgroup of 14 were not different from normal.
Table 2 Major components identified in benzamidine-Sepharose
enriched fractions of patient faeces extracts
Protein name Gene name(s)
Accession
number
Human pancreatric α-amylase 2A AMY2A P04746
Human α-amylase 2B AMY2B P19961
Human trypsin-1 (trypsinogen I) TRY1, PRSS1 P07477
Human trypsin-2 (trypsinogen II) TRY2, PRSS1 P07478
Human trypsin-3/4 (trypsinogen III/IV) TRY3/4, PRSS3/4 P35030
Human chymotrypsin-like elastase
family member 3B
CELA3B P08861
Human carboxypeptidase B CPB1 P15086
Human α-1-antitrypsin SERPINA1 P01009
Alternative names are given where relevant and gene names and the UniProt database
accession numbers are provided for information.
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correlated and, when entered with urgency into a backwards
logistic regression model using the 72 cases with data for all
variables, only depression remained an independent predictor in
the model (p=0.012). Ondansetron slowed transit, increasing
transit time while decreasing FP with a negative correlation
between the rise in transit and the increase in FP (r=−0.40,
p=0.003) in the 55 patients with complete values for both FP
and transit at both time points.
DISCUSSION
We have conﬁrmed previous reports2 that FSP activity is
increased in some patients with IBS-D, but we also show that
there is considerable overlap with normal subjects without IBS.
We increased our understanding of this phenomenon by charac-
terising the proteins responsible for the serine protease activity,
showing that most of this activity is probably due to human pan-
creatic enzymes.
While the pancreas is the most likely source of trypsin-like
activity, enterocytes also contain trypsin mRNA and trypsin-like
immunoreactivity,14 although the amounts are small relative to
expression in the pancreas. However, as has recently been
shown, trypsin levels in colonic biopsies are increased in
IBS-D,15 so we cannot be certain how much of the observed
increase in FP is from enterocytes and how much is pancreatic.
Furthermore, human epithelial cell lines secrete trypsinogen
IV,16 the mRNA of which has also been found to be increased
1.5-fold in human small intestinal biopsies from patients with
IBS-D.17 Trypsinogen IV is known to activate PAR-2 receptors16
and so may be important in activating afferent nerves, inﬂamma-
tory changes and increased permeability, all of which could con-
tribute to IBS symptoms.
Using a benzamindine afﬁnity resin, we extracted FSPs and
characterised them by mass spectrometric analysis of proteo-
lysed components in gel electrophoresis features and identiﬁed
several human enzymes including amylase, elastase, carboxypep-
tidase and trypsin. However, it should be noted that, of these
enzymes, only trypsin is known to activate the PAR-2 receptor
and hence would be predicted to inﬂuence visceral sensitivity,
gut barrier function and immune function. Surprisingly, using a
highly speciﬁc immunoassay we found that endogenous mast
cell tryptase was undetectable in faecal extracts.
Several important papers have examined the release of
trypsin-like mediators from supernatants of IBS biopsies and
most15 18 19 but not all20 have found increased release. Others
have suggested that FSPs might be of bacterial origin, but we
found major components in puriﬁed faecal extract to be human
derived and values of FP rose when bacterial counts were
depleted by MoviPrep, suggesting that any bacterial contribution
to FP is small. Earlier studies argued that, because high levels of
FP activity were not seen in bacterial gastroenteritis, this meant
that fast transit was not important.2 However, we believe our
study is better controlled to study just the effect of fast transit
without other factors which may well be responsible for the
lack of rise in gastroenteritis. Thus, most patients with gastro-
enteritis become anorexic, which would be expected to reduce
pancreatic enzyme secretion, while our subjects ate a 400 kcal
low residue diet the night before the study which would be
expected adequately to stimulate pancreatic secretion.
Since our data suggested a probable pancreatic origin for the
serine protease activity, we examined other pancreatic enzymes
in the stool samples. Faecal amylase was assessed using a speciﬁc
immunoassay to identify human pancreatic amylase and showed
a similar trend to FP with increased values which correlated
with FP activity. The amylase levels suggested two groups of
patients, and we found that patients with IBS-D with higher
faecal amylase had signiﬁcantly higher FP activity and greater
anxiety scores and a tendency to faster transit than those with
lower values, suggesting that these increases might both be due
to accelerated transit. Previous studies of faecal trypsin indicate
that the very substantial amounts of pancreatic trypsin secreted
each day are mostly degraded during transit through the colon
since the 24 h faecal output is approximately 1 mg compared
with an ileostomy output of 50–200 mg.21 Antibiotic therapy
which inhibits bacterial degradation increases faecal trypsin and
elastase in both rats22 and humans.23 The pancreas is the major
source of human faecal elastase since very little is excreted in
the faeces of patients with pancreatic insufﬁciency as assessed by
intubated pancreatic function testing.24 Elastase appears to be
inherently more resistant to bacterial degradation. Thus, after
reducing the faecal bacterial content in humans by oral antibio-
tics, trypsin levels rose 100-fold while elastase levels rose only
2–3-fold.21 This may explain why elastase is not increased in
IBS-D as little degradation occurs, so faecal levels reﬂect pancre-
atic secretion which is not expected to be different in patients
with IBS-D and controls.
We therefore hypothesised that accelerating transit would
increase FP activity and, furthermore, that faster transit in IBS-D
would predict higher FP activity. We tested this as part of our
RCT of ondansetron and were able to show a negative correl-
ation of FP activity with whole gut transit in IBS-D as predicted.
Purging the colon and substantially reducing bacterial counts
using MoviPrep increased FP activity in the stools of healthy
Figure 7 Positive correlation between faecal protease (FP) activity
and days/week with urgency in patients with irritable bowel syndrome
with diarrhoea (Spearman r=0.26, p=0.02, n=73).
Figure 6 Inverse correlation between faecal serine protease (FSP)
activity and whole gut transit in patients with irritable bowel syndrome
with diarrhoea (Spearman r=−0.32, p=0.005, n=79).
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volunteers to levels seen in some patients with IBS-D, support-
ing our hypothesis that raised levels in IBS-D may well reﬂect a
reduction in bacterial degradation of endogenous pancreatic
trypsin secondary to either accelerated transit and/or altered
colonic microbiota.
The increase in FP activity due to undegraded pancreatic
enzymes may well be important since trypsin is a potent activator
of PAR-2 receptors. This activation can increase gut permeabil-
ity2, 25 which, in some animal26 27 and human studies, is very
clearly linked to abdominal pain and visceral hypersensitivity.28
Furthermore, sensitising the distal gut may aggravate diarrhoea
and urgency. Slowing transit by any means would be predicted to
reduce faecal tryptic activity and beneﬁt symptoms. The correl-
ation of FP activity with urgency also suggests that new therapies
targeting FP could be useful in the treatment of this most debili-
tating symptom of IBS-D. Finally, if these changes in FP are due
to changes in the ability of gut microbiota to degrade protease, it
opens up the possibility that modifying the microbiota by diet or
probiotics might beneﬁt IBS symptoms by reducing FP.
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